Claudia Stefanutti

List of Publications by Year
in descending order

110	3,107	186265	175258
papers	citations	28 h-index	52 g-index

124	124	124	2704
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	13.7	624
2	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. JAMA Cardiology, 2020, 5, 217.	6.1	169
3	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an â€œFCS scoreâ€. Atherosclerosis, 2018, 275, 265-272.	0.8	131
4	Clinical Expression of Familial Hypercholesterolemia in Clusters of Mutations of the LDL Receptor Gene That Cause a Receptor-Defective or Receptor-Negative Phenotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, E41-52.	2.4	122
5	Toward an international consensusâ€"Integrating lipoprotein apheresis and new lipid-lowering drugs. Journal of Clinical Lipidology, 2017, 11, 858-871.e3.	1.5	105
6	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 332-335.	1.6	103
7	Severe Hypertriglyceridemiaâ€Related Acute Pancreatitis. Therapeutic Apheresis and Dialysis, 2013, 17, 130-137.	0.9	88
8	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). Clinical Nutrition, 2021, 40, 255-276.	5.0	75
9	Therapeutic Plasma Exchange in Patients With Severe Hypertriglyceridemia: A Multicenter Study. Artificial Organs, 2009, 33, 1096-1102.	1.9	67
10	Lipoprotein apheresis: State of the art and novelties. Atherosclerosis Supplements, 2013, 14, 19-27.	1.2	64
11	The effect of an apolipoprotein A-Iâ€"containing high-density lipoproteinâ€"mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia. American Heart Journal, 2015, 169, 736-742.e1.	2.7	59
12	Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances. Current Atherosclerosis Reports, 2015, 17, 465.	4.8	53
13	Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacological Research, 2016, 105, 198-209.	7.1	53
14	Homozygous autosomal dominant hypercholesterolaemia. Current Opinion in Lipidology, 2015, 26, 200-209.	2.7	52
15	Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 390-396.e8.	1.5	51
16	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 1448-1457.	1.5	48
17	Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks. Transfusion and Apheresis Science, 2004, 31, 3-10.	1.0	43
18	Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine, 2011, 56, 842-849.	3.2	41

#	Article	IF	Citations
19	Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. Journal of Pediatrics, 2015, 167, 338-343.e5.	1.8	40
20	Hypercholesterolaemia â€“ practical information for non-specialists. Archives of Medical Science, 2018, 1, 1-21.	0.9	39
21	Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 1338-1346.e7.	1.5	38
22	Timing clinical events in the treatment of pancreatitis and hypertriglyceridemia with therapeutic plasmapheresis. Transfusion and Apheresis Science, 2011, 45, 3-7.	1.0	36
23	The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia â€“ A post-hoc analysis of a Phase 3, single-arm, open-label trial. Atherosclerosis, 2015, 240, 408-414.	0.8	36
24	The Italian registry of pediatric therapeutic apheresis: A report on activity during 2005. Journal of Clinical Apheresis, 2009, 24, 1-5.	1.3	33
25	Lomitapideâ€“a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2020, 22, 38.	4.8	33
26	Aorta and coronary angiographic followâ€up of children with severe hypercholesterolemia treated with lowâ€density lipoprotein apheresis. Transfusion, 2009, 49, 1461-1470.	1.6	30
27	Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis. Cytokine, 2011, 55, 245-250.	3.2	30
28	Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCVâ€related cryoglobulinemia. Journal of Clinical Apheresis, 2009, 24, 241-246.	1.3	29
29	Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care. Transfusion and Apheresis Science, 2010, 42, 21-26.	1.0	29
30	Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treatedÂinÂRome with lomitapide and lipoproteinÂapheresis. Journal of Clinical Lipidology, 2016, 10, 782-789.	1.5	27
31	Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis, 2016, 254, 179-183.	0.8	26
32	A three month-old infant with severe hyperchylomicronemia: Molecular diagnosis and extracorporeal treatment. Atherosclerosis Supplements, 2013, 14, 73-76.	1.2	25
33	Low-density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 694-701.	1.5	24
34	New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia. Current Medicinal Chemistry, 2012, 19, 4861-4868.	2.4	23
35	A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study. Journal of Clinical Lipidology, 2019, 13, 608-617.	1.5	22
36	Four Novel Partial Deletions of LDL-Receptor Gene in Italian Patients With Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 81-88.	2.4	21

#	Article	IF	Citations
37	Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clinical Science, 2001, 100, 191-198.	4.3	21
38	Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin typeÂ9. Clinical Science, 2015, 129, 63-79.	4.3	21
39	The 2009 2nd Italian Consensus Conference on LDL-apheresis. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 761-762.	2.6	20
40	Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study. Atherosclerosis Supplements, 2009, 10, 89-94.	1.2	19
41	Effects of selective H.E.L.P. LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: Implication for anti-inflammatory response. Cytokine, 2011, 56, 850-854.	3.2	19
42	Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents. Current Atherosclerosis Reports, 2021, 23, 30.	4.8	19
43	Treatment of Homozygous and Double Heterozygous Familial Hypercholesterolemia Children with LDL-Apheresis. International Journal of Artificial Organs, 1995, 18, 103-110.	1.4	18
44	Immunoadsorption apheresis (SelesorbÂ©) in the treatment of chronic hepatitis C virus-related type 2 mixed cryoglobulinemia. Transfusion and Apheresis Science, 2003, 28, 207-214.	1.0	17
45	Treatment of primary hypertriglyceridemia states â€“ General approach and the role of extracorporeal methods. Atherosclerosis Supplements, 2015, 18, 85-94.	1.2	17
46	Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a). Journal of Clinical Lipidology, 2020, 14, 487-497.e1.	1.5	17
47	Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Under Experimental and Clinical Research, 1999, 25, 23-8.	0.3	17
48	Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 36-44.	2.6	16
49	Lipoprotein apheresis downregulates IL-1Î±, IL-6 and TNF-Î± mRNA expression in severe dyslipidaemia. Atherosclerosis Supplements, 2017, 30, 200-208.	1.2	16
50	Efficacy and safety of PCSK9 monoclonal antibodies. Expert Opinion on Drug Safety, 2019, 18, 1191-1201.	2.4	16
51	Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice. Current Atherosclerosis Reports, 2019, 21, 37.	4.8	15
52	Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol. Current Pharmaceutical Design, 2014, 20, 6238-6248.	1.9	15
53	Italian Multicenter Study on Lowâ€Density Lipoprotein Apheresis Working Group 2009 Survey. Therapeutic Apheresis and Dialysis, 2013, 17, 169-178.	0.9	14
54	Efficacy, Safety and Tolerability of???Combined Low-Dose Simvastatin-Fenofibrate Treatment in Primary Mixed Hyperlipidaemia. Clinical Drug Investigation, 2004, 24, 465-477.	2.2	13

#	Article	IF	Citations
55	LDL Apheresis in a Homozygous Familial Hypercholesterolemic Child Aged 4.5. Artificial Organs, 1997, 21, 1126-1127.	1.9	13
56	Effects of Low-Dose Atorvastatin and Rosuvastatin on Plasma Lipid Profiles. American Journal of Cardiovascular Drugs, 2008, 8, 265-270.	2.2	13
57	Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias. Cytokine, 2011, 56, 835-841.	3.2	13
58	ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?. European Heart Journal, 2016, 37, 3596-3599.	2.2	13
59	Combined Treatment with Dif1stat^{Â®} and Diet Reduce Plasma Lipid Indicators of Moderate Hypercholesterolemia More Effectively than Diet Alone: A Randomized Trial in Parallel Groups. Lipids, 2009, 44, 1141-8.	1.7	12
60	Lipid profile and left ventricular geometry pattern in obese children. Lipids in Health and Disease, 2020, 19, 109.	3.0	12
61	Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. Atherosclerosis Supplements, 2017, 30, 86-91.	1.2	10
62	Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis. Atherosclerosis Supplements, 2019, 40, 49-54.	1.2	10
63	Misfolding of Apoprotein B-100, LDL Aggregation and 17-β -estradiol in Atherogenesis. Current Medicinal Chemistry, 2014, 21, 2276-2283.	2.4	10
64	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. Journal of Clinical Medicine, 2021, 10, 4930.	2.4	10
65	Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clinical Science, 2001, 100, 191.	4.3	9
66	Hypercholesterolaemia alters the responses of the plasma lipid profile and inflammatory markers to supplementation of the diet with n-3 polyunsaturated fatty acids from fish oil. European Journal of Clinical Investigation, 2006, 36, 788-795.	3.4	9
67	Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia. Mediators of Inflammation, 2016, 2016, 1-8.	3.0	9
68	LDL Apheresis: A Novel Technique (LIPOCOLLECT 200). Artificial Organs, 2009, 33, 1103-1108.	1.9	8
69	Italian Multicenter Study on Lowâ€Density Lipoprotein Apheresis: Retrospective Analysis (2007). Therapeutic Apheresis and Dialysis, 2010, 14, 79-86.	0.9	8
70	Therapeutic Apheresis in Pregnancy: Three Differential Indications With Positive Maternal and Fetal Outcome. Therapeutic Apheresis and Dialysis, 2016, 20, 677-685.	0.9	8
71	Lipoprotein Apheresis and PCSK9-Inhibitors. Impact on Atherogenic Lipoproteins and Anti-Inflammatory Mediators in Familial Hypercholesterolaemia. Current Pharmaceutical Design, 2019, 24, 3634-3637.	1.9	8
72	Cyclophosphamide and Immunoadsorption Apheresis Treatment of Lupus Nephritis Nonresponsive to Drug Therapy Alone. BioDrugs, 2005, 19, 129-133.	4.6	7

#	Article	IF	Citations
73	A successful term pregnancy with severe hypertriglyceridaemia and acute pancreatitis. Clinical management and review of the literature. Atherosclerosis Supplements, 2019, 40, 117-121.	1.2	7
74	Serum uric acid and left ventricular geometry pattern in obese children. Atherosclerosis Supplements, 2019, 40, 88-93.	1.2	7
75	Comparison of Different Ldl-Apheresis Techniques. International Journal of Artificial Organs, 1998, 21, 66-71.	1.4	6
76	DALI Low-Density Lipoprotein Apheresis in Homozygous and Heterozygous Familial Hypercholesterolemic Patients Using Low-Dose Citrate Anticoagulation. Therapeutic Apheresis and Dialysis, 2001, 5, 364-371.	0.9	6
77	HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?. Blood Transfusion, 2016, 14, 408-12.	0.4	6
78	The 1 and the 2 Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update. Blood Transfusion, 2017, 15, 42-48.	0.4	6
79	Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia. International Journal of Fertility and Menopausal Studies, 1996, 41, 509-15.	0.1	6
80	A new missense mutation (Cys297?Phe) of the low density lipoprotein receptor in Italian patients with familial hypercholesterolemia (FHTrieste). Human Genetics, 1994, 93, 538-40.	3.8	5
81	LDL-apheresis in pediatric patients with severe hyperlipoproteinemia. Journal of Clinical Apheresis, 1995, 10, 101-102.	1.3	5
82	Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia. Medicinal Chemistry, 2012, 8, 1171-1181.	1.5	5
83	Treatment of Severe Genetic Dyslipidemia: Where Are We Going?. Therapeutic Apheresis and Dialysis, 2013, 17, 122-123.	0.9	5
84	First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias. Atherosclerosis Supplements, 2015, 18, 241-250.	1.2	5
85	Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce lowâ€density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report. Journal of Clinical Apheresis, 2018, 33, 546-550.	1.3	5
86	Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia. Medicinal Chemistry, 2012, 8, 1171-1181.	1.5	5
87	Chorionic DNA analysis for the prenatal diagnosis of familial hypercholesterolaemia. Human Genetics, 1993, 92, 424-426.	3.8	4
88	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data in Brief, 2018, 21, 1334-1336.	1.0	4
89	Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL-apheresis. International Journal of Artificial Organs, 1995, 18, 103-10.	1.4	4
90	Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes. Clinical Therapeutics, 2022, 44, 331-348.	2.5	4

#	Article	IF	Citations
91	Severe Hypertriglyceridemiaâ€Related Acute Pancreatitis: Myth or Reality?. Therapeutic Apheresis and Dialysis, 2013, 17, 464-465.	0.9	3
92	Effects of CER-001 on carotid atherosclerosis by 3tmri in homozygous familial hypercholesterolemia (HoFH): The modifying orphan disease evaluation (mode) study. Atherosclerosis, 2014, 235, e13-e14.	0.8	3
93	Targeting MTP for the treatment of homozygous familial hypercholesterolemia. Clinical Lipidology, 2014, 9, 369-381.	0.4	3
94	Geometric complexity identifies platelet activation in familial hypercholesterolemic patients. Microscopy Research and Technique, 2015, 78, 519-522.	2.2	3
95	Hijacked journals are emerging as a challenge for scholarly publishing. Polish Archives of Internal Medicine, 2015, 125, 783-784.	0.4	3
96	Homozygous familial hypercholesterolaemia in childhood â€“ The first case report in Southeast Europe. Atherosclerosis Supplements, 2019, 40, 122-124.	1.2	2
97	A complicated pregnancy in homozygous familial hypercholesterolaemia treated with lipoprotein apheresis: A case report. Atherosclerosis Supplements, 2019, 40, 113-116.	1.2	2
98	Effect of L-carnitine on plasma lipoprotein fatty acids pattern in patients with primary hyperlipoproteinemia. Clinica Terapeutica, 1998, 149, 115-9.	0.1	2
99	Simvastatin and pravastatin: A daily dose of 40 mg in the long-term treatment of primary hypercholesterolemia. Current Therapeutic Research, 1994, 55, 446-454.	1.2	1
100	Association of Serum Selenium with Selected Cardiovascular Risk Factors. Microchemical Journal, 1995, 51, 170-180.	4.5	1
101	Lowâ€ddensity lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 694-701.	1.5	1
102	Scientific Information Security in Information Science and Academic Publishing. Artificial Organs, 2016, 40, 425-430.	1.9	1
103	Lipoprotein and Hemocoagulatory Parameters during Therapeutic Plasmapheresis in Homozygous and Heterozygous Familial Hypercholesterolemia. , 1993, , 223-233.		0
104	A new treatment of refractory ascites: Ascitoapheresis. Journal of Clinical Apheresis, 1996, 11, 46-47.	1.3	0
105	Platelet Activation in Hypercholesterolemic Patients Submitted to Therapeutic Plasmapheresis. An Ultrastructural Study. Hematology, 1997, 2, 491-496.	1.5	0
106	4.P.411 Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Atherosclerosis, 1997, 134, 383.	0.8	0
107	Clinical Trials in Apheresis. Therapeutic Apheresis and Dialysis, 2009, 13, 171-173.	0.9	0
108	LDL-C Therapeutic Target Attainment in Patients with Homozygous Familial Hypercholesterolemia treated with Lomitapide. Atherosclerosis Supplements, 2018, 32, 153-154.	1.2	0

#	Article	IF	Citations
109	Selective continuous removal of low density lipoproteins by dextran sulfate cellulose column adsorption apheresis in the therapy of familial hypercholesterolemia. BeitrÃge Zur Infusionstherapie = Contributions To Infusion Therapy, 1988, 23, 172-82.	0.0	0
110	Pattern of red blood cells and platelets cholesterol and fatty acids in homozygous familial hypercholesterolemic patients treated with LDL-apheresis. Clinica Terapeutica, 1998, 149, 231-3.	0.1	0